P339 - SUPPORTIVE CARE WITH HOME PARENTERAL NUTRITION (HPN) AT END OF LIFE (EOL) IN PATIENTS WITH INTESTINAL FAILURE DUE TO ADVANCED SOLID CANCER

P339

SUPPORTIVE CARE WITH HOME PARENTERAL NUTRITION (HPN) AT END OF LIFE (EOL) IN PATIENTS WITH INTESTINAL FAILURE DUE TO ADVANCED SOLID CANCER

K. Kogovšek^1,*, N. Golob²

¹Department of Clinical Nutrition, ²Department of Acute Palliative Care, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Rationale: We analysed time of introduction and duration of HPN in patients with intestinal failure (IF) due to advanced solid cancer receiving specific oncological treatment. Our second outcome was determining the receipt of aggressive specific oncological treatment at the EoL in the observed population.

Methods: Adult patients with advanced solid cancers who received HPN due to IF as supportive care and died of advanced solid cancer between January 2015 and December 2024 were included into this study. Means/medians as well as frequency distributions/graphic displays were used to describe numerical and categorical variables, respectively.

Results: From 2015–2024, 37 patients with advanced cancer received HPN at the EoL. The absolute number of the patients receiving HPN in our institute is increasing (3 patients in 2015 and 7 patients in 2024). The time of HPN duration varies from 1–1487 days prior to death, with a mean of 176 days and medians of 73,5. 14/37 received HPN for 30 days and less. All patients receiving HPN for 30 days and less were receiving concomitant aggressive cancer treatment. There is an increase in patients receiving HPN 30 days and more before death (1 patient in 2015 and 3 patients in 2024).

Conclusion: Patients with IF due to advanced cancer in early palliative care may benefit from parenteral nutrition as part of their supportive care. In our study, HPN at the EoL was associated with aggressive specific oncological treatment. Receipt of aggressive specific oncological treatment at EoL is associated with higher symptom burden, higher medical costs and lower quality of life of patients. Timely introduction and careful selection of patients for HPN at EoL is advised to increase quality of care at EoL. Further research is needed in order to find an association between receiving HPN and eligibility for receiving aggressive cancer treatment at EoL.

Disclosure of Interest: None declared